Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361079 | 0.89 | CYP2C19 (0.39) | CYP2C19POLBTDP1ALDH1A1LMNA | |
| SCHEMBL7445820 | 0.89 | POLB (0.35) | CYP2C19POLBTDP1ALDH1A1LMNA | |
| SCHEMBL354285 | 0.85 | CYP2C19 (0.37) | CYP2C19POLBTDP1ALDH1A1LMNA | |
| SCHEMBL16150101 | 0.82 | CYP4F2 (0.50) | CYP2C19ALDH1A1LMNACYP4F2CYP4A11 | |
| SCHEMBL5879371 | 0.80 | ZDHHC20 (0.40) | CYP2C19POLBLMNAMAPTCYP4F2 | |
| SCHEMBL2477744 | 0.79 | CYP4F2 (0.39) | POLBTDP1ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL28571904 | 0.79 | — | — | |
| SCHEMBL631049 | 0.78 | CYP2C19 (0.38) | CYP2C19POLBTDP1ALDH1A1LMNA | |
| SCHEMBL2204111 | 0.78 | CYP4F2 (0.39) | POLBALDH1A1CYP4F2CYP4A11DGAT1 | |
| SCHEMBL5000217 | 0.78 | CYP4F2 (0.39) | POLBALDH1A1CYP4F2CYP4A11DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544117-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-01-28 | — | — | US | disclosed |
| US-20170298037-A1 | Novel 5-Hydroxytryptamine Receptor 7 Activity Modulators and Their Method of Use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298037-A1 | Novel 5-Hydroxytryptamine Receptor 7 Activity Modulators and Their Method of Use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-6066666-A | OPTIONALLY N-SUBSTITUTED 3-MONO- AND DI-SUBSTITUTED 2-PYRROLIDINONES AND THIOLACTAM ANALOGS; TREAT SEIZURES, ANXIETY, AND ENHANCING 4-AMINOBUTYRIC ACID (GABA)-INDUCED CHLORIDE CURRENTS AT GABA RECEPTOR/IONOPHORE COMPLEX | WASHINGTON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5776959-A | Anticonvulsant and anxiolytic lactam and thiolactam derivatives | WASHINGTON UNIVERSITY (US) | 1998-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298037-A1 | Novel 5-Hydroxytryptamine Receptor 7 Activity Modulators and Their Method of Use | HTR7, HTR6, HTR5A | CYP2C19 1119/4885POLB 4060/4885TDP1 2588/4885 |
| US-10544117-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | CYP2C19 460/4885POLB 3784/4885TDP1 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.